Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: revised NDI draft expected in 2013, MusclePharm invests, Sundial label and GMP warnings, AHPA publishes organic guidance

This article was originally published in The Tan Sheet

Executive Summary

CFSAN plans revised NDI draft in 2013; MusclePharm invests in BioZone delivery tech; Indiana kicks off anti-smurfing campaign; Sundial fails basic labeling, GMP compliance; AHPA advises supplement firms on organic rules; Naturex commits to sustainability; Targeted Medical Pharma expands into supplements.

You may also be interested in...



Energy Drinks Swayed By Liquid Supplement Draft Guidance After All

Monster Energy products will transition from supplement to conventional food labeling, in a sign that industry may be adapting to FDA’s draft guidance on liquid supplements that stirred controversy upon its publication in 2009.

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.

Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings

Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel